Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03473756
Recruitment Status : Active, not recruiting
First Posted : March 22, 2018
Last Update Posted : May 16, 2022
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : July 16, 2021
Estimated Study Completion Date : December 22, 2023